Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TD-214
- Development stage
- Preclinical
- Lead developer
- TrippBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TD-214 is a small molecule prodrug developed by TrippBio, designed to optimize the delivery of PanCytoVir (probenecid) into the systemic circulation. Currently in preclinical development, TD-214 is being investigated for the treatment of respiratory viral infections, specifically Influenza and Respiratory Syncytial Virus (RSV). The drug functions by inhibiting organic anion transporters (OAT1 and OAT3), which are implicated in viral replication processes. Furthermore, TD-214 is designed to target ACE2, Pannexin 1 (PANX1), and the P2X7 receptor (P2X7R), mechanisms intended to block viral entry and modulate the host's inflammatory response to infection.
02
Targets
ACE2 (Angiotensin-converting enzyme 2)P2RX7 (P2X purinoceptor 7)PANX1 (Pannexin-1)OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)
Beyond the preview
Go deeper on TD-214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TD-214.